Cell-Tx
↗Seoul, South Korea
Cell-Tx (also known as CTX) is a South Korean clinical-stage biotechnology company specializing in the development of next-generation cell therapies using induced pluripotent stem cell (iPSC) technology. The company was founded as a spin-off from Seoul National University Hospital (SNUH) and KAIST to commercialize 'off-the-shelf' and autologous regenerative medicines.
Cell-Tx focuses on two primary therapeutic pillars: Central Nervous System (CNS) disorders and Oncology. Its platform leverages high-purity iPSC differentiation to create dopamine neurons for Parkinson's disease and Natural Killer (NK) cells for solid tumors. The company is led by a team of industry veterans, including CEO Hwang Yu-kyeong, formerly of GC Cell, and is recognized in the Korean biotech ecosystem as a leader in iPSC-based therapeutics.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Cell Therapy & Regenerative Medicine
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M (Pre-revenue)
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$8M
Investors:InterVest, Daily Venture Capital, KDB Bank, Shinhan Capital, Smilegate Investment
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical / Phase 1 (IND-enabling)
Modalities:Cell therapy, iPSC-derived cells, NK cells, CAR-iNK
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Seoul National University Hospital (SNUH), KAIST, Harvard Medical School (Scientific collaboration via Prof. Kwang-soo Kim)
COMPETITION
Position:Emerging
Competitors:Fate Therapeutics, Century Therapeutics, Shoreline Biosciences, GC Cell, NKarta
LEADERSHIP
Key Executives:
Hwang Yu-kyeong - CEO
Kim Kwang-soo - Scientific Founder
Scientific Founders:Hee-Seung Kim, Kim Kwang-soo
Board Members:Hee-Seung Kim, Hwang Yu-kyeong
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cell-Tx. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.